Table 1 Effect of treatment with MMINA on oxidative stress in cisplatin-treated rat organs.

From: Molecular docking, pharmacokinetic studies, and in vivo pharmacological study of indole derivative 2-(5-methoxy-2-methyl-1H-indole-3-yl)-N′-[(E)-(3-nitrophenyl) methylidene] acetohydrazide as a promising chemoprotective agent against cisplatin induced organ damage

Treatments

MDA (ng/mg)

NO (ng/mg)

Liver

Kidney

Heart

Brain

Liver

Kidney

Heart

Brain

Control

45.3 ± 2.11

34.65 ± 3.12

25.65 ± 2.15

32.79 ± 2.65

25.3 ± 1.11

31.65 ± 1.02

27.65 ± 1.17

19.79 ± 0.92

DMSO Vehicle

45.98 ± 2.34

35.01 ± 3.98

25.98 ± 2.01

32. 27 ± 2.34

25.98 ± 1.34

31.01 ± 0.98

27.98 ± 1.01

19. 97 ± 0.74

Cisplatin (12.5 mg/kg)

145.54 ± 3.76****

158.97 ± 4.87****

119.76 ± 5.21****

98.87 ± 3.11****

112.54 ± 2.71****

126.97 ± 3.37****

99.76 ± 5.21****

78.87 ± 1.61****

Cisplatin + MMINA

56.87 ± 3.21*,++++

51.87 ± 3.11*,++++

49.43 ± 3.08*,++++

40.76 ± 1.98++++

36.67 ± 2.21*,++++

40.87 ± 2.30++++

34.43 ± 1.28++++

29.06 ± 0.99*,++++

MMINA (25 mg/kg)

42.12 ± 2.87++++

32.78 ± 2.54++++

23.76 ± 1.97++++

30.23 ± 1.76++++

22.12 ± 1.27++++

30.18 ± 0.99++++

25.76 ± 1.07++++

18.23 ± 0.76 ++++

  1. Data are mean ± SEM, (n = 6). *, ****p < 0.05 and p < 0.0001 versus Control respectively, and ++++p < 0.0001 versus CP. Data analyzed by One-way ANOVA followed by Tukey’s multiple comparison tests.
Back to article page